ViiV Healthcare

News

ViiV ownership shifts as Pfizer sells its stake

Pfizer will relinquish its stake in HIV firm ViiV in a deal valued at $2.1bn that ramps up Shionogi's interest and simplifies its share structure.

News

Four women, seen from the back, hold each other behind each's back

Campaign seeks to plug HIV care gap for UK women

ViiV's campaign wants communication between women and healthcare workers about HIV to move beyond harmful stereotypes and 'risk' labels.

News

ViiV's bimonthly HIV PrEP jab cleared for use by NHS

ViiV's injectable HIV PrEP Apretude will soon be an alternative for people in England and Wales who cannot use daily oral options.

News

FDA sets June date for Gilead's twice-yearly HIV PrEP

Gilead's already dominant position in HIV PrEP could be extended if the FDA approves a new twice-yearly injectable product later this year.

News

GSK's Dovato matches rival Biktarvy with less weight gain

GSK has fired a shot across the bows of Gilead Sciences' HIV juggernaut Biktarvy, with new data showing its rival therapy Dovato is as effective but causes less weight gain.

News

HIV, the AIDS virus (yellow), infecting a human cell

Gilead and MSD say weekly oral therapy controls HIV

Reducing the burden of treatment for people with HIV has been a key objective for drug developers since antiretroviral therapy (ART) first reached the market.

ViiV ownership shifts as Pfizer sells its stake

Campaign seeks to plug HIV care gap for UK women

ViiV's bimonthly HIV PrEP jab cleared for use by NHS

FDA sets June date for Gilead's twice-yearly HIV PrEP

GSK's Dovato matches rival Biktarvy with less weight gain

Gilead and MSD say weekly oral therapy controls HIV

Allogeneic cell therapy isn’t dead, with Brian Culley

How to meet your physicians where they are online

ViiV Healthcare

Editor's Picks